Overexpression of eIF3D in Lung Adenocarcinoma Is a New Independent Prognostic Marker of Poor Survival

Table 1

The association between mRNA expression of eIF3 subunits and clinicopathological parameters of LUAD patients.

(a)

Parameters			eIF3A expression		value	eIF3B expression		value	eIF3C expression		value	eIF3D expression		value
			High ()	Low ()		High ()	Low ()		High ()	Low ()		High ()	Low ()
Age (years, )	<65	219	105	114	0.5870	126	93	0.0050	103	116	0.3195	108	111	0.7856
	≥65	273	138	135		122	151		141	132		139	134
	No data	19
Gender	Females	277	120	157	0.0019	132	145	0.1830	137	140	0.7902	139	138	>0.9999
	Males	234	134	100		126	108		119	115		117	117
Pathological stage	I/II	395	189	206	0.1285	189	206	0.0168	188	207	0.0388	184	206	0.0046
	III/IV	108	61	47		66	42		64	44		68	40
	No data	8
Residual tumour	R0	342	160	182	0.6294	173	169	>0.9999	169	173	>0.9999	163	176	0.0257
	R1/R2	17	9	8		9	8		8	9		13	4
	RX/no data	152
Smoking history	1	75	29	46	0.0336	32	43	0.1679	34	41	0.3807	41	34	0.3807
	2/3/4/5	422	220	202		219	203		217	205		205	217
	No data	14
Radiation therapy	No	396	204	192	0.1616	194	202	0.0483	196	200	>0.9999	188	208	0.1232
	Yes	58	24	34		37	21		29	29		34	24
	No data	57
Targeted molecular therapy	No	302	146	156	0.2308	143	159	0.0361	154	148	0.4245	138	164	0.0357
	Yes	150	82	68		87	63		70	80		85	65
	No data	59
Mutations in KRAS/EGFR/ALK	No	132	68	64	0.8935	65	67	0.1790	65	67	0.4230	78	54	0.3455
	Yes	95	50	45		38	57		52	43		50	45
	No data	284

(b)

Parameters		eIF3E expression		value	eIF3F expression		value	eIF3G expression		value	eIF3H expression		value	eIF3I expression		value
		High ()	Low ()		High ()	Low ()		High ()	Low ()		High ()	Low ()		High ()	Low ()
Age (years, )	<65	103	116	0.3652	94	125	0.0367	112	107	0.7861	111	108	0.7856	110	109	0.7856
	≥65	140	133		144	129		136	137		134	139		133	140
	No data
Gender	Females	141	136	0.6574	148	129	0.0622	157	120	0.0034	134	143	0.3749	141	136	0.5945
	Males	114	120		105	129		102	132		123	111		113	121
Pathological stage	I/II	186	209	0.0297	189	206	0.1599	195	200	0.4484	186	209	0.0066	198	197	>0.9999
	III/IV	64	44		60	48		58	50		67	41		54	54
	No data
Residual tumour	R0	172	170	0.0456	178	164	0.6275	176	166	0.3280	178	164	0.2123	184	158	0.4592
	R1/R2	13	4		10	7		11	6		12	5		11	6
	RX/no data
Smoking history	1	35	40	0.7074	34	41	0.5315	44	31	0.1329	32	43	0.2107	42	33	0.2113
	2/3/4/5	209	213		210	212		206	216		215	207		202	220
	No data
Radiation therapy	No	190	206	0.3274	195	201	0.7789	200	196	0.8890	192	204	0.1616	191	205	0.8883
	Yes	32	26		27	31		30	28		34	24		29	29
	No data
Targeted molecular therapy	No	149	153	0.8417	153	149	0.3180	159	143	0.3181	148	154	0.7650	141	161	0.4841
	Yes	72	78		68	82		71	79		76	74		76	74
	No data
Mutations in KRAS/EGFR/ALK	No	78	54	0.1252	77	55	0.8913	64	68	0.2853	72	60	0.1723	81	51	0.4148
	Yes	66	29		57	38		53	42		61	34		53	42
	No data

(c)

Parameters		eIF3J expression		value	eIF3K expression		value	eIF3L expression		value	eIF3M expression		value
		High; ()	Low; ()		High; ()	Low; ()		High; ()	Low; ()		High; ()	Low; ()
Age (years, )	<65	102	117	0.2772	102	117	0.2772	93	126	0.0050	104	115	0.5865
	≥65	141	132		141	132		151	122		137	136
	No data
Gender	Females	129	148	0.1839	145	132	0.2488	144	133	0.2869	142	135	0.4778
	Males	123	111		110	124		110	124		112	122
Pathological stage	I/II	183	212	0.0299	192	203	0.2792	191	204	0.4479	187	208	0.0505
	III/IV	63	45		59	49		57	51		63	45
	No data
Residual tumour	R0	165	177	0.8057	172	170	0.6211	170	172	0.6205	170	172	0.3208
	R1/R2	9	8		10	7		10	7		11	6
	RX/no data
Smoking history	1	36	39	0.9011	36	39	0.8031	39	36	0.7073	38	37	0.8024
	2/3/4/5	206	216		210	212		207	215		205	217
	No data
Radiation therapy	No	190	206	0.6734	191	205	0.3295	199	197	>0.9999	189	207	>0.9999
	Yes	30	28		32	26		29	29		28	30
	No data
Targeted molecular therapy	No	138	164	0.1099	154	148	0.3202	147	155	0.3181	141	161	0.5489
	Yes	81	69		69	81		81	69		75	75
	No data
Mutations in KRAS/EGFR/ALK	No	86	46	0.0206	70	62	>0.9999	71	61	0.1013	75	57	0.6855
	Yes	47	48		50	45		62	33		51	44
	No data

Indicates statistical significance ().